Biogen has announced the publication of new clinical trial data that further underscores the clinical benefits of the spinal muscular atrophy (SMA) therapy Spinraza.
In association with Ionis Pharmaceuticals, the company has published end-of-study results from CHERISH, a phase III study evaluating Spinraza in the treatment of later-onset spinal SMA, in the New England Journal of Medicine.
“Biogen has published new clinical data showing the effectiveness of Spinraza in the treatment of later-onset spinal muscular atrophy.“
It was shown that Spinraza demonstrated stabilisation or improvements in motor function in individuals with SMA who would otherwise be expected to experience a decline over time, with the majority experiencing benefits in upper limb and general motor function, including crawling and standing with support.
Following a positive interim analysis, Biogen ended the CHERISH study early so all participants could have the option to receive Spinraza as part of the SHINE open-label extension study.
Dr Alfred Sandrock, executive vice-president and chief medical officer at Biogen, said: "As the first and only approved treatment for SMA, the data published in the New England Journal of Medicine continue to underscore the benefit of Spinraza for individuals with later-onset SMA."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical